720 related articles for article (PubMed ID: 31173696)
1. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
Zhang Y; Chen ML; Zhou Y; Yi L; Gao YX; Ran L; Chen SH; Zhang T; Zhou X; Zou D; Wu B; Wu Y; Chang H; Zhu JD; Zhang QY; Mi MT
Mol Nutr Food Res; 2015 Aug; 59(8):1443-57. PubMed ID: 25943029
[TBL] [Abstract][Full Text] [Related]
3. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
4. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.
Zeng X; Yang J; Hu O; Huang J; Ran L; Chen M; Zhang Y; Zhou X; Zhu J; Zhang Q; Yi L; Mi M
Antioxid Redox Signal; 2019 Jan; 30(2):163-183. PubMed ID: 29310441
[No Abstract] [Full Text] [Related]
5. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
6. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
7. Folic acid attenuates high-fat diet-induced steatohepatitis
Xin FZ; Zhao ZH; Zhang RN; Pan Q; Gong ZZ; Sun C; Fan JG
World J Gastroenterol; 2020 May; 26(18):2203-2220. PubMed ID: 32476787
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
9. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
Liu H; Zhong H; Yin Y; Jiang Z
Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression.
Cheng K; Song Z; Zhang H; Li S; Wang C; Zhang L; Wang T
Med Mol Morphol; 2019 Dec; 52(4):187-197. PubMed ID: 30673851
[TBL] [Abstract][Full Text] [Related]
11. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
[TBL] [Abstract][Full Text] [Related]
12. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway.
Yang Y; Qiu W; Xiao J; Sun J; Ren X; Jiang L
J Transl Med; 2024 Mar; 22(1):309. PubMed ID: 38532480
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism.
Zhou R; Yi L; Ye X; Zeng X; Liu K; Qin Y; Zhang Q; Mi M
Cell Physiol Biochem; 2018; 51(5):2397-2420. PubMed ID: 30537742
[TBL] [Abstract][Full Text] [Related]
14. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
15. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
16. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
Izdebska M; Piątkowska-Chmiel I; Korolczuk A; Herbet M; Gawrońska-Grzywacz M; Gieroba R; Sysa M; Czajkowska-Bania K; Cygal M; Korga A; Dudka J
Can J Physiol Pharmacol; 2017 Dec; 95(12):1442-1453. PubMed ID: 28759727
[TBL] [Abstract][Full Text] [Related]
18. PRDX6 Promotes Fatty Acid Oxidation
Shen W; Yang L; Yang Y; Wang P; Tao X; Shen Y; Wang S; Shen Y
Antioxid Redox Signal; 2023 Jun; 38(16-18):1184-1200. PubMed ID: 36401357
[No Abstract] [Full Text] [Related]
19. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
[TBL] [Abstract][Full Text] [Related]
20. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD
Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
